🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Belgium
Clinical trial register · European Union · CTIS

Clinical Trials in Belgium

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42 Clear sponsor filter
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
17 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
A Study to Learn How Different Manufactured Products of the Study Medicine Called Osivelotor (PF-07940367) Taste and Are Taken Up Into the Blood When Mixed With Soft Foods or Liquids Given on an Empty Stomach or Given With Food or an Acid Reducing Agent in Healthy Adults
2024-511410-20-01Sickle Cell Disease
Pfizer Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Belgium
07/09/2026
Phase I
C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity
2026-526334-67-00chronic weight management and other weight-related co-morbi…
Pfizer Inc.
Nutritional and Metabolic Diseases
Belgium
01/07/2026
Phase I
A Study to Learn About How Different Forms of Study Medicine Prifetrastat are Taken Up Into the Blood in Healthy Adults
2026-526038-26-00Locally advanced or metastatic ER+/HER2- breast cancer
Pfizer Inc.
Neoplasms
Belgium
17/06/2026
Phase I
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
2025-525125-12-00Migraine with or without aura
Pfizer Inc.
Nervous System Diseases
Belgium
28/04/2026
Phase I
A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up into the Blood of Healthy Adults After Taking Different Tablets of the Study Medicine Called Ibuzatrelvir.
2025-525041-43-00Coronavirus disease 2019
Pfizer Inc.
Virus Diseases
Belgium
01/04/2026
Phase I
A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin® (somatropin) Delivery and Taken Up Into the Blood in Healthy Adults
2026-525165-52-00Growth hormone deficiency
Pfizer Inc.
Hormonal diseases
Belgium
25/03/2026
Phase III
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
2025-523521-18-00Metastatic Colorectal Cancer
Pfizer Inc.
Neoplasms
Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark
23/03/2026
Phase I
A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 are Tolerated and Act in the Body of Healthy Adults
2025-523759-76-01Rheumatoid arthritis and Systemic Lupus Erythematosus
Pfizer Inc.
Immune System Diseases
Belgium
17/03/2026
Phase I
A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 mg Tablet in Healthy Adults Under Fed Conditions
2026-525342-29-00Transthyretin amyloidosis
Pfizer Inc.
Pathological Conditions, Signs and Symptoms
Belgium
11/03/2026
Phase III
C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
2024-519369-24-00METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Pfizer Inc.
Not possible to specify
Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece
22/12/2025
Phase III
C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
2025-522093-36-00Cancer cachexia
Pfizer Inc.
Nutritional and Metabolic Diseases
Slovakia, Italy, Belgium, Germany, Spain, France, Bulgaria, Poland
16/12/2025
Phase II
C5001004 - A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension
2025-521155-23-00Pulmonary Arterial Hypertension
Pfizer Inc.
Cardiovascular Diseases
Italy, Czechia, Germany, Greece, Spain, Belgium, France
02/12/2025
Phase III
C5851005 - PADLINK-005: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
2025-521281-97-00Non-Small Cell Lung Cancer (NSCLC)
Pfizer Inc.
Neoplasms
Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria
17/11/2025
Phase III
C4551002 - An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
2025-520566-22-00Hormone Receptor-Positive, HER2-Negative Advanced/Metastati…
Pfizer Inc.
Neoplasms
Hungary, Bulgaria, Czechia, Slovakia, Netherlands, Spain, Greece, Finland, Belgium, Sweden, Poland, Germany, France, Italy
20/10/2025
Phase I
A Study to Learn How Different Forms of The Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults
2025-522574-36-00Primary and secondary hypertension, and heart failure
Pfizer Inc.
Cardiovascular Diseases
Belgium
10/10/2025
Phase I
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
2025-522331-34-00locally advanced or metastatic ER+/HER2- breast cancer
Pfizer Inc.
Neoplasms
Belgium
09/09/2025
Phase II
C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma
2024-517866-40-00Moderate-to-severe Asthma
Pfizer Inc.
Respiratory Tract Diseases
Belgium, Hungary, Spain, Bulgaria, Italy, Poland, Czechia
26/08/2025
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe/country/belgium

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.